Clinical Trials Logo

Filter by:
NCT ID: NCT01655589 Recruiting - Clinical trials for Macular Degeneration

VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents

Start date: January 2008
Phase: N/A
Study type: Observational

The main purpose of this study is to investigate the association between VEGF gene polymorphism and the response to intravitreal drugs in neovascular age-related macular degeneration. This is a retrospective review of patients treated between 2008 and 2012 at the Institute of Vision, in Belo Horizonte, Brazil.

NCT ID: NCT01655576 Completed - Clinical trials for Management of Delivery

Effectiveness of Placental Drainage in the Third Stage of Labor: a Randomized Clinical Trial

PLADRAINAGE
Start date: August 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if placental drainage shortens third period of labor and reduces postpartum blood lost.

NCT ID: NCT01655108 Active, not recruiting - Clinical trials for Female Pattern Alopecia

Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients

Start date: March 2012
Phase: Phase 3
Study type: Interventional

This study aims to investigate the effectiveness and safety of mesotherapy for the treatment of female pattern alopecia. - Sixty female subjects between 18 and 65 years diagnosed with female pattern hair loss will undergo mesotherapy sessions weekly for ten weeks. - One group will receive 0.5%/2ml minoxidil application and a control group will receive application of placebo (saline 0.9%). - Biopsy of the scalp, trichogram and trichoscopy (Fotofinder) will be performed before and 08 weeks after treatment as a method objective evaluation of the response

NCT ID: NCT01655069 Completed - Clinical trials for Urinary Bladder, Overactive

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076

LEOPARD
Start date: October 4, 2012
Phase: Phase 3
Study type: Interventional

This was a 40-week study to investigate how safe and effective solifenacin solution was in treating children or adolescents with symptoms of overactive bladder (OAB), who completed study 905-CL-076 (NCT01565707).

NCT ID: NCT01655030 Completed - Bipolar I Disorder Clinical Trials

Creatine Monohydrate as Adjuvant Therapy for Bipolar Depression

Start date: July 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether creatine monohydrate is effective as an adjuvant treatment for bipolar depression.

NCT ID: NCT01654237 Completed - Clinical trials for Musculoskeletal Disorder

Musculoskeletal Complaints in an Industry

FIPMCAWMI
Start date: October 2010
Phase: N/A
Study type: Interventional

The hypothesis of this study is that there will be a variety of factors influencing the musculoskeletal complaints among workers of different sectors. Work-related musculoskeletal disorders (WMSDs) account for more than 30% of occupational diseases in the world. In order to organize the strategic actions that will be developed for the prevention of MSDs, it is essential to analyze in advance the peculiar situations of the different sectors of a workplace. The objectives of this study were to determine the prevalence of musculoskeletal complaints among workers in a medium-sized industry by comparing its sectors and to investigate the influence of occupational and non-occupational factors in the increase of complaints.

NCT ID: NCT01653587 Completed - Clinical trials for Acute Coronary Syndrome

AngioSeal Versus Radial Approach in Acute Coronary Syndrome

ARISE
Start date: July 2012
Phase: Phase 4
Study type: Interventional

Among non-ST-segment elevation acute coronary syndrome patients submitted to early invasive strategy and randomized for the transfemoral or transradial approach, the AngioSeal vascular closure device would decrease the prevalence of vascular complications at puncture site, reaching the non-inferiority criterion when compared to the radial access.

NCT ID: NCT01653041 Completed - Clinical trials for Kidney Transplantation

Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors

Start date: August 2012
Phase: Phase 4
Study type: Interventional

Recipients from living donors kidneys HLA-identical were lower risk for acute rejection, graft loss or death. There is no clear definition of what is ideal immunosuppressive regimen for this population. Everolimus (EVR) was associated with lower incidence of viral infections and also the lowest incidence of neoplasms. Furthermore, immunosuppressive regimens based everolimus allow the reduction or elimination of calcineurin inhibitors reducing cardiovascular risks associated with chronic use of these agents. Moreover, the use of EVR is associated with increased incidence of proteinuria, which associated mechanism has not been fully elucidated. Knowing that proteinuria may be the first indication of recurrence of the underlying renal disease, detailed information about the patient's medical history and histological analysis of the graft may contribute with additional knowledge in this area. The aim of this prospective, open, single arm study that will be performed only in the Hospital do Rim e Hipertensão, is investigating the outcomes of kidney transplantation in recipients of HLA identical living donor, receiving an everolimus-based immunosuppressive regimen. This will include 100 recipients of first or second kidney transplant from a living donor HLA identical to the Kidney and Hypertension Hospital, which will be followed by a period of 12 months.

NCT ID: NCT01652638 Not yet recruiting - Healthy Clinical Trials

PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (SUBCUTANEOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALS

Start date: February 2013
Phase: Phase 1
Study type: Interventional

The objective of this clinical, randomized, crossover, is to assess the pharmacodynamic profile of the drug Heparin Sodium from swine (intravenously), manufactured and marketed by Laboratory Blau Farmacêutica S/A, compared to the product of Heparin Sodium ® company APP Pharmaceuticals, through the determination of activity of the following markers: - Anti-FXa; - Anti-FIIA.

NCT ID: NCT01651923 Not yet recruiting - Healthy Clinical Trials

PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (INTRAVENOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALS

Start date: February 2013
Phase: Phase 1
Study type: Interventional

The objective of this clinical, randomized, crossover, is to assess the pharmacodynamic profile of the drug Heparin Sodium from swine (intravenously), manufactured and marketed by Laboratory Blau Farmacêutica S/A, compared to the product of Heparin Sodium ® company APP Pharmaceuticals, through the determination of activity of the following markers: - Anti-FXa; - Anti-FIIA.